Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation
Completed · Phase 2/Phase 3 · Has a placebo group
Conditions studied: Heart Transplantation, Liver Transplantation, Bone Resorption
In brief
The purpose of this study is to compare the effectiveness and safety of zoledronic acid with alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is given as a single intravenous infusion. Alendronate is given as a weekly pill. Both are expected to be very effective, but it is not known which one will work best.
Key facts
- Study ID
- NCT00297830
- Run by
- Columbia University
- People needed
- 111
- Starts
- 2005-11-01
- Expected to finish
- 2014-01-01
- Last updated by the study team
- 2018-08-16
Who can join
Age: 20 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- A man or woman, aged 20 to 70, of any race who has had a heart or liver transplant
You may not qualify if…
- hyperparathyroidism
- Paget's disease
- hyperthyroidism
- cancer
- severe kidney disease,
- intestinal disease
- active peptic ulcer disease
- current or past treatment for osteoporosis
- pregnancy or lactation
- severe oral/dental disease
Where it is running
- Columbia University Medical Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.